Literature DB >> 24124322

Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Bassam Abu-Wasel1, Caolan Walsh, Valerie Keough, Michele Molinari.   

Abstract

Polycystic liver diseases (PLD) represent a group of genetic disorders in which cysts occur in the liver (autosomal dominant polycystic liver disease) or in combination with cysts in the kidneys (autosomal dominant polycystic kidney disease). Regardless of the genetic mutations, the natural history of these disorders is alike. The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts. Both genders are affected; however, women have a higher prevalence. Most patients with PLD are asymptomatic and can be managed conservatively. Severe symptoms can affect 20% of patients who develop massive hepatomegaly with compression of the surrounding organs. Rrarely, patients with PLD suffer from acute complications caused by the torsion of hepatic cysts, intraluminal cystic hemorrhage and infections. The most common methods for the diagnosis of PLD are cross sectional imaging studies. Abdominal ultrasound and computerized tomography are the two most frequently used investigations. Magnetic resonance imaging is more sensitive and specific, and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction. Different treatment modalities are available to physicians caring for these patients. Medical treatment has been ineffective. Percutaneous sclerotherapy, trans-arterial embolization, cyst fenestration, hepatic resection and liver transplantation are indicated to specific groups of patients and have to be tailored according to the extent of disease. This review outlines the current knowledge of the pathophysiology, clinical course, diagnosis and treatment strategies of PLD.

Entities:  

Keywords:  Classification; Epidemiolgy; Genetic; Hepatic; Polycystic liver disease; Therapy

Mesh:

Year:  2013        PMID: 24124322      PMCID: PMC3793132          DOI: 10.3748/wjg.v19.i35.5775

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  122 in total

Review 1.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

Review 2.  Systematic review: the pathophysiology and management of polycystic liver disease.

Authors:  F Temmerman; L Missiaen; B Bammens; W Laleman; D Cassiman; C Verslype; J van Pelt; F Nevens
Journal:  Aliment Pharmacol Ther       Date:  2011-07-26       Impact factor: 8.171

Review 3.  Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities.

Authors:  V J Desmet
Journal:  Mayo Clin Proc       Date:  1998-01       Impact factor: 7.616

Review 4.  Surgery for adult polycystic liver disease.

Authors:  C Soravia; G Mentha; E Giostra; P Morel; A Rohner
Journal:  Surgery       Date:  1995-03       Impact factor: 3.982

5.  Laparoscopic treatment of simple hepatic cysts and polycystic liver disease.

Authors:  P Fiamingo; U Tedeschi; M Veroux; U Cillo; A Brolese; A Da Rold; C Madia; G Zanus; D F D'Amico
Journal:  Surg Endosc       Date:  2003-02-10       Impact factor: 4.584

Review 6.  Liver transplantation for adult polycystic liver disease.

Authors:  K Swenson; P Seu; M Kinkhabwala; M Maggard; P Martin; J Goss; R Busuttil
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

7.  Liver cysts in autosomal-dominant polycystic kidney disease: clinical and computed tomographic study.

Authors:  E Levine; L T Cook; J J Grantham
Journal:  AJR Am J Roentgenol       Date:  1985-08       Impact factor: 3.959

8.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

9.  Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin.

Authors:  G T Everson; M Emmett; W R Brown; P Redmond; D Thickman
Journal:  Hepatology       Date:  1990-04       Impact factor: 17.425

10.  Clinical profile of autosomal dominant polycystic liver disease.

Authors:  Qi Qian; Airong Li; Bernard F King; Patrick S Kamath; Donna J Lager; John Huston; Clarence Shub; Sonia Davila; Stefan Somlo; Vicente E Torres
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  26 in total

1.  Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation.

Authors:  Kiyotaka Uchiyama; Kazuya Honda; Ryochi Yoshida; Yuka Kamijo; Mai Yanagi; Mineo Nakatsuka; Yoshitaka Ishibashi
Journal:  CEN Case Rep       Date:  2016-07-27

Review 2.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

3.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

Review 4.  A Practical Approach to Polycystic Liver Disease.

Authors:  Armani Patel; Arlene B Chapman; Adam E Mikolajczyk
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

5.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

Review 6.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

Review 7.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression.

Authors:  Timothy L Kline; Panagiotis Korfiatis; Marie E Edwards; Joshua D Warner; Maria V Irazabal; Bernard F King; Vicente E Torres; Bradley J Erickson
Journal:  Nephrol Dial Transplant       Date:  2015-08-31       Impact factor: 5.992

9.  Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Authors:  William J Brock; James J Beaudoin; Jason R Slizgi; Mingming Su; Wei Jia; Sharin E Roth; Kim L R Brouwer
Journal:  Int J Toxicol       Date:  2018 Mar/Apr       Impact factor: 2.032

Review 10.  Polycystic Liver Disease: Advances in Understanding and Treatment.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Annu Rev Pathol       Date:  2021-11-01       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.